Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A

References

• Manco-JohnsonMJ, AbshireTC, ShapiroAD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–544. doi:10.1056/NEJMoa06765917687129
   PubMed Web of Science ®Google Scholar
• Manco-JohnsonMJ, SoucieJM, GillJC. Joint outcomes committee of the universal data collection USHTCN. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood. 2017;129(17):2368–2374. doi:10.1182/blood-2016-02-68316928183693
   PubMed Web of Science ®Google Scholar
• RodriguezV, MancusoME, WaradD, et al. Central venous access device (CVAD) complications in haemophilia with inhibitors undergoing immune tolerance induction: lessons from the international immune tolerance study. Haemophilia. 2015;21(5):e369–e74. doi:10.1111/hae.1274026178581
   PubMed Web of Science ®Google Scholar
• GouwSC, van der BomJG, LjungR, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368(3):231–239. doi:10.1056/NEJMoa120802423323899
   PubMed Web of Science ®Google Scholar
• PeyvandiF, MannucciPM, GaragiolaI, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374(21):2054–2064. doi:10.1056/NEJMoa151643727223147
   PubMed Web of Science ®Google Scholar
• CalvezT, ChambostH, Claeyssens-DonadelS, et al. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood. 2014;124(23):3398–3408. doi:10.1182/blood-2014-07-58634725253771
   PubMed Web of Science ®Google Scholar
• EttingshausenCE, KreuzW. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: a prospective clinical case series. Haemophilia. 2010;16(1):90–100. doi:10.1111/hae.2009.16.issue-119878335
   PubMed Web of Science ®Google Scholar
• MorfiniM, AuerswaldG, KobeltRA, et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European haemophilia centres. Haemophilia. 2007;13(5):502–507. doi:10.1111/hae.2007.13.issue-517880436
   PubMed Web of Science ®Google Scholar
• NegrierC, DargaudY, BordetJC. Basic aspects of bypassing agents. Haemophilia. 2006;12(Suppl 6):48–52; discussion −3. doi:10.1111/j.1365-2516.2006.01366.x
   Web of Science ®Google Scholar
• RosenfeldSB, WatkinsonKK, ThompsonBH, MacfarlaneDE, LentzSR. Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient. Thromb Haemost. 2002;87(5):925–926. doi:10.1055/s-0037-161311012038803
   PubMed Web of Science ®Google Scholar
• AledortLM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost. 2004;2(10):1700–1708. doi:10.1111/jth.2004.2.issue-1015456478
   PubMed Web of Science ®Google Scholar
• WalshCE, SoucieJM, MillerCH. United States hemophilia treatment center N. Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol. 2015;90(5):400–405. doi:10.1002/ajh.v90.525616111
   PubMed Web of Science ®Google Scholar
• MonahanPE, BakerJR, RiskeB, SoucieJM. Physical functioning in boys with hemophilia in the U.S. Am J Prev Med. 2011;41(6 Suppl 4):S360–S368. doi:10.1016/j.amepre.2011.09.01722099359
   PubMed Web of Science ®Google Scholar
• MorfiniM, HayaS, TagarielloG, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia. 2007;13(5):606–612. doi:10.1111/hae.2007.13.issue-517880451
   PubMed Web of Science ®Google Scholar
• DiMicheleDM, HootsWK, PipeSW, RivardGE, SantagostinoE. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007;13(Suppl 1):1–22. doi:10.1111/j.1365-2516.2007.01497.x
   PubMed Web of Science ®Google Scholar
• WightJ, PaisleyS, KnightC. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia. 2003;9(4):436–463. doi:10.1046/j.1365-2516.2003.00781.x12828679
   PubMed Web of Science ®Google Scholar
• LentingPJ, DenisCV, ChristopheOD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017;130(23):2463–2468. doi:10.1182/blood-2017-08-80166229042366
   PubMed Web of Science ®Google Scholar
• KitazawaT, IgawaT, SampeiZ, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10):1570–1574. doi:10.1038/nm.294223023498
   PubMed Web of Science ®Google Scholar
• UchidaN, SambeT, YoneyamaK, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016;127(13):1633–1641. doi:10.1182/blood-2015-06-65022626626991
   PubMed Web of Science ®Google Scholar
• ShimaM, HanabusaH, TakiM, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374(21):2044–2053. doi:10.1056/NEJMoa151176927223146
   PubMed Web of Science ®Google Scholar
• ShimaM, HanabusaH, TakiM, et al. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv. 2017;1(22):1891–1899. doi:10.1182/bloodadvances.201700668429296836
   PubMed Web of Science ®Google Scholar
• YoneyamaK, SchmittC, KotaniN, et al. A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A. Clin Pharmacokinet. 2017.
   Web of Science ®Google Scholar
• OldenburgJ, MahlanguJN, KimB, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809–818. doi:10.1056/NEJMoa170306828691557
   PubMed Web of Science ®Google Scholar
• den UijlIE, FischerK, Van Der BomJG, GrobbeeDE, RosendaalFR, PlugI. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia. 2011;17(1):41–44. doi:10.1111/hae.2010.17.issue-120825504
   PubMed Web of Science ®Google Scholar
• SoedaT, KitazawaT, MutoA, et al. In vitro characterization of ACE910, a humanized bispecific antibody to factors IXa and X. Haemophilia. 2014;20(S3):77.
   Google Scholar
• MullerJ, PekrulI, PotzschB, BerningB, OldenburgJ, SpannaglM. Laboratory monitoring in emicizumab-treated persons with hemophilia A. Thromb Haemost. 2019;119(9):1384–1393. doi:10.1055/s-0039-169242731203578
   PubMed Web of Science ®Google Scholar
• PipeSW, ShimaM, LehleM, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6(6):e295–e305. doi:10.1016/S2352-3026(19)30054-731003963
   PubMed Web of Science ®Google Scholar
• ChowdaryP, CarcaoM, HolmePA, et al. Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A. Res Pract Thromb Haemost. 2019;3(3):542–554. doi:10.1002/rth2.1222031294338
   PubMed Web of Science ®Google Scholar
• LissitchkovT, KlukowskaA, PasiJ, et al. Efficacy and safety of simoctocog alfa (Nuwiq(R)) in patients with severe hemophilia A: a review of clinical trial data from the GENA program. Ther Adv Hematol. 2019;10:2040620719858471. doi:10.1177/204062071985847131263528
   PubMed Web of Science ®Google Scholar
• ShahA, CoyleT, LalezariS, et al. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: comprehensive pharmacokinetic assessment from clinical studies. Haemophilia. 2018;24(5):733–740. doi:10.1111/hae.1356129963724
   PubMed Web of Science ®Google Scholar
• SwystunLL, OgiwaraK, RawleyO, et al. Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients. Blood. 2019;134(11):880–891. doi:10.1182/blood.201900019031350267
   PubMed Web of Science ®Google Scholar
• YoungG, LiesnerR, ChangTY, et al. A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127–2138.31697801
   PubMed Web of Science ®Google Scholar
• ShimaM, NogamiK, NagamiS, et al. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia. 2019. doi:10.1111/hae.13848
   Web of Science ®Google Scholar
• MahlanguJ, OldenburgJ, Paz-PrielI, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811–822. doi:10.1056/NEJMoa180355030157389
   PubMed Web of Science ®Google Scholar
• JonssonF, SchmittC, PetryC, MercierF, FreyN, RetoutS. Exposure-response modeling of emicizumab for the prophylaxis of bleeding in hemophilia A patients with and without inhibitors against factor VIII. Res Pract Thromb Haemost. 2019;3(Suppl 1):315.31294318
   PubMed Web of Science ®Google Scholar
• HayCR, PalmerB, ChalmersE, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood. 2011;117(23):6367–6370. doi:10.1182/blood-2010-09-30866821471523
   PubMed Web of Science ®Google Scholar
• BargAA, AvishaiE, BudnikI, et al. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort. Pediatr Blood Cancer. 2019;66(11):e27886. doi:10.1002/pbc.2788631348595
   PubMed Web of Science ®Google Scholar
• CatarinoC, CampanicoS, RodriguesF, et al. Prophylaxis with emicizumab in children and adults with hemophilia A and inhibitors: preliminary data on 7 patients of a portuguese hemophilia center. Res Pract Thromb Haemost. 2019;3(Suppl 1):299.
   Google Scholar
• YoungG, SidonioRF, LiesnerR, et al. HAVEN 2 updated analysis: multicenter, open-label, phase 3 study to evaluate efficacy, safety and pharmacokinetics of subcutaneous administration of emicizumab prophylaxis in pediatric patients with hemophilia A with inhibitors. Blood. 2017;130(Suppl1):85.
   Google Scholar
• CarcaoM, Escuriola-EttingshausenC, SantagostinoE, et al. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia. 2019;25(4):676–684. doi:10.1111/hae.1376231033112
   PubMed Web of Science ®Google Scholar
• YoungG. How I treat children with haemophilia and inhibitors. Br J Haematol. 2019;186(3):400–408. doi:10.1111/bjh.1594231069799
   PubMed Web of Science ®Google Scholar
• AstermarkJ, DonfieldSM, DiMicheleDM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood. 2007;109(2):546–551. doi:10.1182/blood-2006-04-01798816990605
   PubMed Web of Science ®Google Scholar
• Le QuellecS, NegrierC. Emicizumab should be prescribed independent of immune tolerance induction. Blood Adv. 2018;2(20):2783–2786. doi:10.1182/bloodadvances.201801585930352952
   PubMed Web of Science ®Google Scholar
• YoungG. Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance. Blood Adv. 2018;2(20):2780–2782. doi:10.1182/bloodadvances.201801584230352951
   PubMed Web of Science ®Google Scholar
• DimicheleDM, HayCR. The international immune tolerance study: a multicenter prospective randomized trial in progress. J Thromb Haemost. 2006;4(10):2271–2273. doi:10.1111/jth.2006.4.issue-1016848866
   PubMed Web of Science ®Google Scholar
• NogamiK, MatsumotoT, TabuchiY, et al. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab. J Thromb Haemost. 2018;16(6):1078–1088. doi:10.1111/jth.2018.16.issue-629645406
   PubMed Web of Science ®Google Scholar
• BatsuliG, ZimowskiKL, TickleK, MeeksSL, SidonioRF Jr. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis. Haemophilia. 2019;25(5):789–796. doi:10.1111/hae.v25.531373431
   PubMed Web of Science ®Google Scholar
• NilssonIM, BerntorpE, LofqvistT, PetterssonH. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232(1):25–32. doi:10.1111/joim.1992.232.issue-11640190
   PubMed Web of Science ®Google Scholar
• Kruse-JarresR, OldenburgJ, SantagostinoE, et al. Bleeding and safety outcomes in persons with haemophilia A without inhibitors: results from a prospective non-interventional study in a real-world setting. Haemophilia. 2019;25(2):213–220. doi:10.1111/hae.1365530724422
   PubMed Web of Science ®Google Scholar
• KlingeJ, AubergerK, AuerswaldG, BrackmannHH, Mauz-KorholzC, KreuzW. Prevalence and outcome of intracranial haemorrhage in haemophiliacs–a survey of the paediatric group of the German Society of Thrombosis and Haemostasis (GTH). Eur J Pediatr. 1999;158(Suppl 3):S162–S165. doi:10.1007/PL0001434610650860
   PubMed Web of Science ®Google Scholar
• OldenburgJ, LevyGG. Emicizumab prophylaxis in hemophilia A with Inhibitors. N Engl J Med. 2017;377(22):2194–2195. doi:10.1056/NEJMoa170306829171814
   PubMed Web of Science ®Google Scholar
• HartmannR, FeenstraT, ValentinoL, DockalM, ScheiflingerF. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents. J Thromb Haemost. 2018. doi:10.1111/jth.14203
   PubMed Web of Science ®Google Scholar
• MancusoME, CallaghanMU, Kruse-JarresR, et al. Emicizumab prophylaxis in adolescent/adult patients with hemophilia A previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the HAVEN 1 study. Blood. 2017;130(Suppl 1):1071.28838942
   PubMedGoogle Scholar
• MakrisM, IorioA, LentingPJ. Emicizumab and thrombosis: the story so far. J Thromb Haemost. 2019;17(8):1269–1272. doi:10.1111/jth.v17.831368220
   PubMed Web of Science ®Google Scholar
• KnoeblP, MarcoP, BaudoF, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622–631. doi:10.1111/j.1538-7836.2012.04654.x22321904
   PubMed Web of Science ®Google Scholar
• ChalmersEA. Heritable thrombophilia and childhood thrombosis. Blood Rev. 2001;15(4):181–189. doi:10.1054/blre.2001.016611792119
   PubMed Web of Science ®Google Scholar
• YadaK, NogamiK. Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations. J Blood Med. 2019;10:171–181. doi:10.2147/JBM.S17595231308776
   PubMed Web of Science ®Google Scholar
• Samuelson BannowB, RechtM, NegrierC, et al. Factor VIII: long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Rev. 2019;35:43–50. doi:10.1016/j.blre.2019.03.00230922616
   PubMed Web of Science ®Google Scholar
• Rodriguez-MerchanEC, ValentinoLA. Increased bone resorption in hemophilia. Blood Rev. 2019;33:6–10. doi:10.1016/j.blre.2018.05.00229857920
   PubMed Web of Science ®Google Scholar
• PoonJL, ZhouZY, DoctorJN, et al. Quality of life in haemophilia A: hemophilia Utilization Group Study Va (HUGS-Va). Haemophilia. 2012;18(5):699–707. doi:10.1111/j.1365-2516.2012.02791.x22507546
   PubMed Web of Science ®Google Scholar
• von MackensenS, Myrin WestessonL, KavakliK, et al. The impact of psychosocial determinants on caregivers’ burden of children with haemophilia (results of the BBC study). Haemophilia. 2019;25(3):424–432. doi:10.1111/hae.2019.25.issue-330974034
   PubMed Web of Science ®Google Scholar
• De MoerlooseP, UrbancikW, Van Den BergHM, RichardsM. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia. 2008;14(5):931–938. doi:10.1111/hae.2008.14.issue-518684125
   PubMed Web of Science ®Google Scholar
• WileyRE, KhouryCP, SnihurAWK, et al. From the voices of people with haemophilia A and their caregivers: challenges with current treatment, their impact on quality of life and desired improvements in future therapies. Haemophilia. 2019;25(3):433–440. doi:10.1111/hae.1375431016823
   PubMed Web of Science ®Google Scholar
• FerreiraAA, LeiteIC, Bustamante-TeixeiraMT, et al. Health-related quality of life in hemophilia: results of the hemophilia-specific quality of life index (Haem-a-Qol) at a Brazilian blood center. Rev Bras Hematol Hemoter. 2013;35(5):314–318. doi:10.5581/1516-8484.2013010824255613
   PubMedGoogle Scholar
• KhairK, KlukowskaA, Myrin WestessonL, et al. The burden of bleeds and other clinical determinants on caregivers of children with haemophilia (the BBC study). Haemophilia. 2019;25(3):416–423. doi:10.1111/hae.2019.25.issue-330925018
   PubMed Web of Science ®Google Scholar
• PoonJL, DoctorJN, NicholMB. Longitudinal changes in health-related quality of life for chronic diseases: an example in hemophilia A. J Gen Intern Med. 2014;29(Suppl 3):S760–S766. doi:10.1007/s11606-014-2893-y25029975
   PubMed Web of Science ®Google Scholar
• WitkopM, NeffA, BucknerTW, et al. Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Haemophilia. 2017;23(4):556–565. doi:10.1111/hae.2017.23.issue-428419637
   PubMed Web of Science ®Google Scholar
• MahlanguJ, OldenburgJ, CallaghanMU, et al. Health-related quality of life and health status in persons with haemophilia A with inhibitors: a prospective, multicentre, non-interventional study (NIS). Haemophilia. 2019;25(3):382–391. doi:10.1111/hae.2019.25.issue-331016855
   PubMed Web of Science ®Google Scholar
• PollakE, MuhlanH, Von MackensenS, BullingerM, Haemo-QolG. The Haemo-QoL Index: developing a short measure for health-related quality of life assessment in children and adolescents with haemophilia. Haemophilia. 2006;12(4):384–392. doi:10.1111/j.1365-2516.2006.01292.x16834738
   PubMed Web of Science ®Google Scholar